ArticleCancer science2013
Selective ablation of tumor-associated macrophages suppresses metastasis and angiogenesis.
Article in Cancer science, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Legumain in cardiovascular diseases.Experimental biology and medicine (Maywood, N.J.) · 2024Review
- Depletion of tumor-associated macrophages inhibits lung cancer growth and enhances the antitumor effect of cisplatin.Cancer science · 2023Article
- Antitumor Therapy Targeting the Tumor Microenvironment.Journal of oncology · 2023Review
- Anti-Inflammatory Mechanisms of Dietary Flavones: Tapping into Nature to Control Chronic Inflammation in Obesity and Cancer.International journal of molecular sciences · 2022Review
- Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy.Cancers · 2022Review
- Enzyme-Activatable Chemokine Conjugates for In Vivo Targeting of Tumor-Associated Macrophages.Angewandte Chemie (Weinheim an der Bergstrasse, Germany) · 2022Article
- Enzyme-Activatable Chemokine Conjugates for In Vivo Targeting of Tumor-Associated Macrophages.Angewandte Chemie (International ed. in English) · 2022Article
- Autocrine pro-legumain promotes breast cancer metastasis via binding to integrin αvβ3.Oncogene · 2022Article
- Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer.BMC cancer · 2022Article
- Immune cell targeting nanoparticles: a review.Biomaterials research · 2021Review
- The Mechanism of Asparagine Endopeptidase in the Progression of Malignant Tumors: A Review.Cells · 2021Review
- The Tumor Proteolytic Landscape: A Challenging Frontier in Cancer Diagnosis and Therapy.International journal of molecular sciences · 2021Review
- Tumor Associated Macrophages, as the Dominant Immune Cells, Are an Indispensable Target for Immunologically Cold Tumor-Glioma Therapy?Frontiers in cell and developmental biology · 2021Review
- Metabolic programming of tumor associated macrophages in the context of cancer treatment.Annals of translational medicine · 2020Review
- Review
- The exosomal integrin α5β1/AEP complex derived from epithelial ovarian cancer cells promotes peritoneal metastasis through regulating mesothelial cell proliferation and migration.Cellular oncology (Dordrecht, Netherlands) · 2020Article
- Friend or Foe? Recent Strategies to Target Myeloid Cells in Cancer.Frontiers in cell and developmental biology · 2020Review
- Article
- Tumor-associated macrophages: role in cancer development and therapeutic implications.Cellular oncology (Dordrecht, Netherlands) · 2019Review
- Cysteine Cathepsins in Tumor-Associated Immune Cells.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Tumor-associated macrophages (TAM) play a critical role in promoting tumor development and metastasis. In the present study, we found that legumain, an asparaginyl endopeptidase, was highly expressed on the surface of TAM. A doxorubicin-based prodrug specifically activated by legumain selectively ablated TAM and resulted in a significant reduction of angiogenic factors and related tumor vessel growth. Treatment with the prodrug also suppressed circulating tumor cells and myeloid immune suppressor Gr-1+/CD11b+ cells in tumor-bearing animals. After selective ablation of TAM using the prodrug, tumor growth and metastases were greatly inhibited in murine tumor models. These results indicate that legumain-activated prodrugs targeting TAM in tumors might represent a novel anticancer strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.